Analyst Anticipates Puration Inc Sales to Reach $3 Million in 2019 With Hemp-based CBD Market Growing to $1.9 Billion

DALLAS, November 20, 2018 /PRNewswire/ --

Puration, Inc.(USOTC: PURA) today announced that Goldman Small Cap Research issued a research update on the Company. The report includes a 'speculative-buy' rating with a target price-per-share of $0.25. The report previews upcoming milestones and provides an analysis of Puration's recent financial results and new initiatives. To view the update report, along with disclosures and disclaimers, visit http://www.GoldmanResearch.com or view the report on the company's website at https://www.purationinc.com/goldman-3q2018-update.

Puration Goldman Small Cap Research Report Highlights  
Puration, Inc. is a leading Texas-based, CBD-infused beverage provider. The Company's flagship product, EVERx, which was introduced in 2017, targets the sports nutrition market. Puration plans to introduce new beverages organically in addition to making targeted acquisitions. The Company recently spun-off its cannabis cultivation segment to focus its efforts exclusively on its high-growth core CBD-infused beverage business.

According to Hemp Business Journal, the overall hemp-based CBD market is forecast to grow from $820 million in 2017 to $1.9 billion in 2022 and given that the market remains fragmented, fast-growing PURA is well positioned to capture market share very quickly.

In the Opportunity Research update, analyst Rob Goldman discusses the Company's strong financials, and exciting upcoming opportunities that lie ahead.

Goldman noted, "PURA announced very strong 3Q18 results and the best is yet to come. As a result, we believe that current prices represent a terrific entry point for opportunistic investors. Moreover, we expect PURA could return to its 52-week high of $0.25 early next year, on the heels of products with new, upgraded packaging which will begin reaching stores next week. PURA's new package form is priced at a convenient $20 per 4-pack. Management believes that this new form will take sales to the next level."

"We believe our forecasts are conservative. For 2019, we estimate sales will reach $3M, with operating profit of $800,000. It should be noted that these figures exclude any contributions from new products which are likely to be introduced in the coming weeks. Separately, an under the radar near-term catalyst is the pending dividend related to the transaction with Nouveau Life Pharmaceuticals, (OTC - NOUV). NOUV formally declared a 1:5 stock dividend whereby NOUV common will be issued to PURA shareholders at a ratio of one NOUV common share for every five shares of PURA held on the yet to be determined date of record.  Although this event is not factored into the current stock price, we believe these shares could rise ahead of the record date announcement."

About Goldman Small Cap Research
Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, stock market blogs, and popular investment newsletters.

Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published sponsored company research report on Alternet Systems, Inc. which carries a rating and a price target.  The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from Puration, Inc. ("the Company") authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.

Separate from the factual content of our report about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

A Goldman Small Cap Research report, update, newsletter, article, trading alert, corporate profile, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only.  Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other regulatory agency. To download this research report or any of our research, view our disclosures and disclaimers, or for more information, visit http://www.goldmanresearch.com. Goldman Small Cap Research was compensated $5500 by the Company for research and distribution services. GSCR was not compensated for the production and distribution of this update.

About Puration, Inc. (OTC: PURA)
Puration, Inc. is a leading Texas-based, CBD-infused beverage provider. The Company's flagship product, EVERx, which was introduced in 2017, targets the sports nutrition market. Puration plans to introduce new beverages as well as grow it product portfolio organically as well as through targeted acquisitions. As of October 2018, the Company was set to spin off its cannabis cultivation segment to focus its efforts exclusively on its high-growth core CBD-infused beverage business.

For more information, please visit: http://www.PurationInc.com
Goldman Small Cap Research
Rob Goldman, Analyst
+410-609-7100
rob@goldmanresearch.com

SOURCE Puration, Inc.